-
公开(公告)号:SK286972B6
公开(公告)日:2009-08-06
申请号:SK2312000
申请日:1998-08-10
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/00 , C07D237/14 , A61K31/00 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/00 , A61P19/02 , A61P29/00 , A61P31/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: Described are pyridazinone compounds of formula (I) which are cyclooxygenase inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), which is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号:CZ300570B6
公开(公告)日:2009-06-17
申请号:CZ20011481
申请日:1999-10-27
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFEY J , COGHLAN MICHAEL J , STEWART ANDREW O
IPC: C07D237/14 , A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
Abstract: Predložený vynález popisuje slouceniny pyridazinonu, které jsou inhibitory cyklooxygenasy (COX), zejména jsou selektivními inhibitory cylkooxygenasy-2 (Cox-2), Cox-2 je indukovatelná izoforma související se zánetem na rozdíl od konstitutivní izoformy, cyklooxygenasy-1 (Cox-1), která je duležitým "udržujícím" enzymem v mnoha tkáních, vcetne gastrointestinálního traktu (GI) a ledvin. Selektivita techto sloucenin pro Cox-2 minimalizuje nežádoucí vedlejší úcinky GI a renální oblasti, které jsou u bežne prodávaných, nesteroidních, protizánetlivých léciv (NSAID). Farmaceutická kompozice obsahující therapeuticky úcinné množství slouceniny a farmaceuticky prijatelný nosic. Použití této slouceniny pro výrobu léciva pro inhibici biosyntézy prostaglandinu u savce pri potrebe takového ošetrení. Použití slouceniny pro výrobu léciva pro ošetrení bolesti, horecky, zánetu, revmatické artritity, osteoartritidy, adheze a karcinomu.
-
公开(公告)号:CA2691782A1
公开(公告)日:2009-03-19
申请号:CA2691782
申请日:2008-09-11
Applicant: ABBOTT LAB
Inventor: LIU HUAQING , COWART MARLON D , MARSH KENNAN C , LEE JAE YO , BECONI MARIA G , BLACK LAWRENCE A , WETTER JILL M , CUSTER THOMAS C
IPC: C07D487/04 , A61K31/501 , A61P25/00
Abstract: The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prod rugs of CNS-active compounds, compositions comprising such compounds, method s for making the compounds, salts, and polymorphs, and methods of treating c onditions and disorders using such compounds and compositions. Octahydro-pyr rolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antag onists, and are useful in treating conditions or disorders prevented by or a meliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole N-oxide compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
-
公开(公告)号:ECSP099046A
公开(公告)日:2009-02-27
申请号:ECSP099046
申请日:2009-01-09
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , LIU HUAQING , BLACK LAWRENCE A , BENNANI YOUSSEF L
IPC: C07D207/06 , C07D401/10
Abstract: Compuestos con la fórmula (I) consta gráfico que son útiles para tratar condiciones o trastornos que se pueden prevenir o mejorar mediante los ligandos del receptor de histamina.3. También se divulgan composiciones farmacéuticas que comprenden los ligandos del receptor de histamina-3 y para sus composiciones, y un proceso para preparar compuestos dentro del alcance de la fórmula (I)
-
公开(公告)号:DOP2008000083A
公开(公告)日:2009-01-31
申请号:DO2008000083
申请日:2008-12-19
Applicant: ABBOTT LAB
Inventor: LIU HUAQING , BLACK LAWRENCE A , BENNANI YOUSSEF L , COWART MARLON D
IPC: C07D207/06
-
86.
公开(公告)号:MX2008010805A
公开(公告)日:2008-09-01
申请号:MX2008010805
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: BARNES DAVID M , KOLACZKOWSKI LAWRENCE , CHANG SOU-JEN , BLACK LAWRENCE A , COWART MARLON D , GREGG ROBERT J , ZHENG GUO ZHU , SUN MINGHUA , ZHAO CHEN , WITTENBERGER STEVEN J , HENRY RODGER F , HAIGHT ANTHONY R , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , FICKES MICHAEL G
IPC: C07D487/04 , A61K31/407
Abstract: Se describen en la presente derivados de octahidropirrolo[3,4-b]pi rrol o una sal farmacéuticamente aceptable, éster, amida, profármaco, o forma radiomarcada del mismo, en donde R1 es alquilo, cicloalquilo de 03-05, o (cicloalquilo de 03- C5)metilo: R2a, R2, R2C, R2d, R2e y R2 son cada uno independientemente hidrógeno, metilo o fluorometilo; R3a, R3b, R3C y R3d son cada uno independientemente hidrógeno, alquilo, fluoroalquilo, fluoroalcoxi, alcoxi, tioalcoxi, halógeno, o nitrilo, con la condición de que cuando uno o más de R3, R3b, R3C y R3d son alquilo, entonces al menos uno de R3, R3b, R3° y R3d es fluoroalquilo, fluoroalcoxi, alcoxi, tioalcoxi, halógeno o nitrilo: L1 es un enlace, oxígeno, azufre, carbonilo, alquileno, alquilcarbonilo, alquilamino, -C(=N-Oalquilo)-, NR4, -C(=O)NR4-, o -NR4C(=O)-; o R4 es hidrógeno o alquilo; Cy1 es arilo, cicloalquilo, cicloalquenilo, heteroarilo, o heterociclo; Z es un sustituyente R6 o un grupo representado por -L3-0y3 R6 es hidrógeno, acilo, aciloxi, alquenilo, alcoxi, alcoxialcoxi, alcoxialq u ib, alcoxicarbonibo, alcoxi i mino, alcoxisulfon ib, alquilo, alquilcarbonibo, alquilsulfonibo, alquinilo, amido, carboxi, ciano, cicloalquibo, fluoroalcoxi, haloalcoxi, haboalquilo, halógeno, hidroxi, hidroxialquilo, mercapto, nitro, alquiltio, amino, NHR7, NR7R8, -N(R7)C(0)R9, -C(=O)NR7R8, o N(R7)S02(R10); [3 es un enlace, oxígeno, azufre, carbonilo, alquileno, alquilcarbonilo, alquilamino, -C(N-Oalquilo)-, NR11, C(=O)NR11-, o -NR11C(=O)-; Cy3 es arilo, cicloalquilo, cicloalquenilo, heteroarilo o heterociclo; R7, R8, R9, R1° y R11 en cada caso son independientemente hidrógeno, alquilo de C14, cicloalquilo de C34, o una (cicloalquilo de C3-C4)amina; son útiles en el tratamiento de condiciones o trastornos prevenidos por o mejorados por ligandos del receptor de histamina 3. También se describen compuesto de octahidro-pirrolo[3,4- b]pirrol, métodos para utilizar tales compuestos, composiciones para fabricarlos, y procesos para preparar tales compuestos.
-
87.
公开(公告)号:CA2641624A1
公开(公告)日:2007-09-07
申请号:CA2641624
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: ZHAO CHEN , ZHANG GEOFF G Z , SHEIKH AHMAD Y , GREGG ROBERT J , KOLACZKOWSKI LAWRENCE , LOU XIAOCHUN , COWART MARLON D , SUN MINGHUA , CHANG SOU-JEN , ZHENG GUO ZHU , HAIGHT ANTHONY R , BLACK LAWRENCE A , WITTENBERGER STEVEN J , FICKES MICHAEL G , BARNES DAVID M , HENRY RODGER F
IPC: C07D487/04 , A61K31/407
Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
-
公开(公告)号:PL194175B1
公开(公告)日:2007-05-31
申请号:PL35541898
申请日:1998-08-10
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号:CA2566898A1
公开(公告)日:2005-12-01
申请号:CA2566898
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: NERSESIAN DIANA L , PU YU-MING , CURTIS MICHAEL P , BLACK LAWRENCE A , ALTENBACH ROBERT J , GFESSER GREGORY A , LUKIN KIRILL A , CHANG SOU-JEN , LIU HUAQING , KU YI-YIN , FAGHIH RAMIN , COWART MARLON D
IPC: C07D495/04 , A61K31/4709 , A61K31/4725 , C07D401/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/02 , C07D471/04 , C07D487/04 , C07D491/02 , C07D491/04 , C07D498/02 , C07D513/04
Abstract: Compounds of formula (I) wherein R 1 or R 2 is a tricyclic or bicyclic ring, each of which contains at least two hctcroatoms, and R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, X, X', Y, Y', Z, and Z' arc as defined hcrcin, arc useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
-
公开(公告)号:NO315423B1
公开(公告)日:2003-09-01
申请号:NO20000863
申请日:2000-02-22
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
-
-
-
-
-
-
-
-